Compounds > arsenic trioxide
Page last updated: 2024-08-21

arsenic trioxide and darinaparsin

arsenic trioxide has been researched along with darinaparsin in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Colombo, M; Diaz, Z; Komarnitsky, PB; Kourelis, M; Mann, KK; Marcoux, S; Miller, WH1
Boise, LH; Cai, Y; Croutch, C; Gutman, D; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L1
Knox, SJ; Li, X; Nolley, R; Peehl, DM; Reese, SW; Tian, J; Young, SR; Zhao, H1
del Rincon, SV; Diaz, Z; Garnier, N; Gupta, A; Kourelis, M; Kwan, S; Mann, KK; Miller, WH; Molina, MF; Petruccelli, LA; Schipper, HM1
Bohle, DS; Conklin, DS; Dahabieh, MS; del Rincon, SV; Garnier, N; Gu, Y; Mann, KK; Miller, WH; Nichol, JN; Redstone, GG; Sun, Y1

Other Studies

5 other study(ies) available for arsenic trioxide and darinaparsin

ArticleYear
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
    Leukemia, 2008, Volume: 22, Issue:10

    Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Hematologic Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Multidrug Resistance-Associated Proteins; Oncogene Proteins, Fusion; Oxidative Stress; Oxides

2008
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cysteine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Multiple Myeloma; Oxides

2009
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jun-15, Volume: 18, Issue:12

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Hypoxia; Glutathione; Humans; Intestines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxides; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Radiation-Sensitizing Agents; Reactive Oxygen Species; Xenograft Model Antitumor Assays

2012
The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells.
    Leukemia, 2013, Volume: 27, Issue:11

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatin Immunoprecipitation; Cytoprotection; DNA Helicases; Flow Cytometry; Glutathione; Heme Oxygenase-1; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Nuclear Proteins; Oxides; Phosphorylation; Promoter Regions, Genetic; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured

2013
The novel arsenical darinaparsin is transported by cystine importing systems.
    Molecular pharmacology, 2014, Volume: 85, Issue:4

    Topics: Amino Acid Transport System y+; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cysteine; gamma-Glutamyltransferase; Glutathione; Humans; Oxides; Sulfhydryl Compounds

2014